114 related articles for article (PubMed ID: 10362115)
21. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
Lyass O; Hubert A; Gabizon AA
Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
[TBL] [Abstract][Full Text] [Related]
22. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group.
Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA;
J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667
[TBL] [Abstract][Full Text] [Related]
23. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of the treatment of high-risk endometrial cancer with concurrent weekly paclitaxel and cisplatin and whole abdominal radiation therapy: a Gynecologic Oncology Group study.
McMeekin DS; Walker JL; Hartenbach EM; Bookman MA; Koh WJ;
Gynecol Oncol; 2009 Jan; 112(1):134-41. PubMed ID: 18962846
[TBL] [Abstract][Full Text] [Related]
25. Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Kondo K; Kobayashi M; Kojima H; Hirabayashi N; Kataoka M; Araki K; Matsui T; Takiyama W; Miyashita Y; Nakazato H; Nakao A; Sakamoto J
Jpn J Clin Oncol; 2005 Jun; 35(6):332-7. PubMed ID: 15961435
[TBL] [Abstract][Full Text] [Related]
26. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
Polee MB; Verweij J; Siersema PD; Tilanus HW; Splinter TA; Stoter G; Van der Gaast A
Eur J Cancer; 2002 Jul; 38(11):1495-500. PubMed ID: 12110496
[TBL] [Abstract][Full Text] [Related]
28. Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Schena M; Barone C; Birocco N; Dongiovanni D; Numico G; Colantonio I; Bertetto O
Cancer Chemother Pharmacol; 2005 Mar; 55(3):271-6. PubMed ID: 15592837
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
Breathnach OS; Georgiadis MS; Schuler BS; Pizzella P; Llorens V; Kasturi V; Steinberg SM; O'Neil K; Takimoto CH; Johnson BE
Clin Cancer Res; 2000 Jul; 6(7):2670-6. PubMed ID: 10914708
[TBL] [Abstract][Full Text] [Related]
30. Weekly paclitaxel and nedaplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer: a phase I/II study.
Hasegawa Y; Takanashi S; Okudera K; Aoki M; Basaki K; Kondo H; Takahata T; Yasui-Furukori N; Tateishi T; Abe Y; Okumura K
Jpn J Clin Oncol; 2004 Nov; 34(11):647-53. PubMed ID: 15613553
[TBL] [Abstract][Full Text] [Related]
31. Phase I and pharmacokinetic study of carboplatin and paclitaxel with a biweekly schedule in patients with advanced non-small-cell lung cancer.
Ichiki M; Gohara R; Fujiki R; Hoashi S; Rikimaru T; Aizawa H
Cancer Chemother Pharmacol; 2003 Jul; 52(1):67-72. PubMed ID: 12743738
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer.
Polee MB; Eskens FA; van der Burg ME; Splinter TA; Siersema PD; Tilanus HW; Verweij J; Stoter G; van der Gaast A
Br J Cancer; 2002 Mar; 86(5):669-73. PubMed ID: 11875723
[TBL] [Abstract][Full Text] [Related]
33. Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.
Watanabe H; Yamamoto N; Tamura T; Shimoyama T; Hotta K; Inoue A; Sawada M; Akiyama Y; Kusaba H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Kodama T; Saijo N
Jpn J Clin Oncol; 2003 Dec; 33(12):626-30. PubMed ID: 14769840
[TBL] [Abstract][Full Text] [Related]
34. Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan.
Takahashi N; Kashiwagi H; Iwabuchi S; Yamazaki Y; Yanaga K
Am J Clin Oncol; 2005 Jun; 28(3):242-7. PubMed ID: 15923795
[TBL] [Abstract][Full Text] [Related]
35. Liposomal cisplatin: a new cisplatin formulation.
Stathopoulos GP
Anticancer Drugs; 2010 Sep; 21(8):732-6. PubMed ID: 20671511
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study.
Fleming GF; Fowler JM; Waggoner SE; Copeland LJ; Greer BE; Horowitz I; Sutton G; Schilder RJ; Fracasso PM; Ball HG; McGuire WP
J Clin Oncol; 2001 Feb; 19(4):1021-9. PubMed ID: 11181665
[TBL] [Abstract][Full Text] [Related]
38. High-dose biweekly intraperitoneal cisplatin: an effective way to increase cisplatin dose intensity.
Bonetti A; Howell SB; McClay E; Kirmani S; Goel R; Plaxe S; Braly P; Kim S
Gynecol Oncol; 1993 Jun; 49(3):318-24. PubMed ID: 8314533
[TBL] [Abstract][Full Text] [Related]
39. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Otterson GA; Lavelle J; Villalona-Calero MA; Shah M; Wei X; Chan KK; Fischer B; Grever M
Invest New Drugs; 2005 Dec; 23(6):555-62. PubMed ID: 16034523
[TBL] [Abstract][Full Text] [Related]
40. Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study.
Stathopoulos GP; Rigatos SK; Stathopoulos J
Anticancer Res; 2010 Apr; 30(4):1317-21. PubMed ID: 20530446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
